Currently, three JAK inhibitors (JAKi) are licensed or soon to be adopted in SpA‐associated arthropathy including tofacitinib (considered a pan‐JAKi), upadacitinib (predominantly JAK1 inhibition, with reports of JAK2 inhibition in certain assays ranging from 2‐ to 60‐fold less selectivity than JAK1) and deucravacitinib (highly selective Tyk2 inhibition).9, 10, 11, 12, 13, 14. Here, TYK2 is linked to arthropathy.